Company	Price	Valuation					Profitability					Cash & leverage					Quality				Rating
		P/E	P/B	P/S	EV / EBITDA	DCF upside	Gross margin	Operating margin	Net margin	ROE	ROIC	FCF yield	Debt / equity	Net debt / EBITDA	Interest coverage	Current ratio	Dividend yield	Piotroski (0-9)	Altman Z	Rating score (1-5)
WVEthis companyWave Life Sciences Ltd.	$3.29	-14.05×	5.45×	67.1×	-11.67×	-66.1%	79.3%	-504.1%	-478.3%	-38.8%	-39.0%	-6.5%	0.03×	2.99×	0×	6.47×	0.0%	2	-0.46	2	C
ALNYAlnylam Pharmaceuticals, Inc.	$156.13	166.38×	66.01×	14.03×	81.9×	-1017.9%	81.8%	13.5%	8.4%	39.8%	13.7%	0.9%	1.62×	-0.6×	1.99×	2.76×	0.0%	5	3.79	4	A-
ARCTArcturus Therapeutics Holdings Inc.	$10.42	-2.55×	0.78×	2.5×	0.61×	-144.1%	95.5%	-111.5%	-97.9%	-30.7%	-31.4%	-44.2%	0.12×	3.28×	0×	6.64×	0.0%	1	-0.72	2	C
ARWRArrowhead Pharmaceuticals, Inc.	$48.01	-2,827.05×	9.9×	5.56×	28.84×	-253.1%	100.0%	11.9%	-0.2%	-0.3%	4.6%	3.4%	0.79×	0.85×	1.1×	4.86×	0.0%	3	2.67	1	D+
BNTCBenitec Biopharma Inc.	$9.31	-13.65×	3.52×	0×	-8.75×	-68.5%	0.0%	0.0%	0.0%	-25.7%	-28.8%	-2.7%	0×	3.53×	0×	34×	0.0%	1	43.49	2	C+
IONSIonis Pharmaceuticals, Inc.	$28.90	-33.24×	25.88×	13.41×	-52.41×	-292.2%	98.3%	-40.5%	-40.4%	-77.9%	-12.0%	-2.5%	5.35×	-7.89×	-4.22×	3.83×	0.0%	2	0.89	1	D+
Peer median	—	-13.65×	9.9×	5.56×	0.61×	-253.1%	95.5%	0.0%	-0.2%	-25.7%	-12.0%	-2.5%	0.79×	0.85×	0×	4.86×	0.0%	2	2.67	2	—